Previous 10 | Next 10 |
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acut...
ACM,ADAP,APRN,AUD,AVDL,AZUL,BLDP,BNTX,BTAI,COTY,DTIL,DUK,EGRX,ELAN,ENR,FOLD,GSL,HEP,HGV,JLL,KNDI,KOS,LINC,MAC,MDGL,MRSN,MSGE,MTBC,OSG,PLTR,PRTY,RCM,RIDE,SPTN,TGNA,THS,TSN,VRTV,VTRS,WOW,WTRG For Seeking Alpha's full earnings season calendar, click here. For further details see: Nota...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) , a commercial-stage biopharmaceutical company that uses artificial intelligence to develop neuroscience and immuno-oncology therapies, rose 12.9% this week, according to data from S&P Global Market Intelligence . The stock c...
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, ...
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023 Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022 NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage bioph...
Shares of small-cap stocks are typically more likely to double (or more) in a short period, say, one year. But these companies also tend to be substantially riskier than more-established corporations. That's why it's essential to proceed with extreme caution when looking at these smaller co...
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, today announce...
Shares of BioXcel Therapeutics (NASDAQ:BTAI) have added 5.6% to $15.60 in premarket trading on Tuesday, after the biopharmaceutical company announced $260M in strategic financing and formed a new unit to develop oncology-focused medicines. Under the new strategic financing agreements with fun...
Checkmate Pharmaceuticals (CMPI) +332% Regeneron to acquire Checkmate Pharma in $250 million all-cash deal. Axsome Therapeutics (AXSM) +27%. Super Micro Computer (SMCI) +16% on raised Q3 guidance. 4D pharma (LBPS) +13%. American Campus Communities (ACC) +13% Blac...
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lea...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...